Tuesday, 26 April 2011
ANN ARBOR, Mich, April 26, 2011 – Everist Health, a prognostics company focused on developing gene-based molecular assays with applications in cancer, cardiovascular, metabolic and neurodegenerative diseases, today announced that world-renowned biochemist and Nobel Prize winner Dr. Kary Mullis will be the keynote speaker for its June 5th Gala Dinner at the Field Museum in Chicago. The Gala event coincides with the 2011 American Society of Clinical Oncology (ASCO) Annual Meeting and marks an opportunity to celebrate the pivotal role that scientific creativity and innovation plays in advancing the practice of medicine.
Monday, 07 March 2011
ANN ARBOR, Mich. – March 7, 2011 – Everist Health announced today that it has received U.S. Clinical Laboratory Improvement Amendment (CLIA) certification required for the company to launch its OncoDefender-CRC assay, a prognostic test for assessing the risk of cancer recurrence for patients with early stage colorectal cancer. Because OncoDefender-CRC is categorized by CLIA as a high complexity test, it is evaluated against the most stringent federally-mandated requirements, ensuring that the company’s testing laboratory meets quality standards for accuracy, reliability and timeliness of patient results.
Monday, 10 January 2011
ANN ARBOR, Mich, January 10, 2011 – Genetics Squared, a prognostics company focused on developing gene-based molecular assays for the prediction of cancer recurrence, today announced that it will change its corporate name to Everist Health and has appointed Prasad Sunkara, Ph.D. as its new President and Chief Executive Officer, effective immediately.